Abstract Library

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4619 Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study

Introduction: Radioligand therapy with lutetium-177 labelled somatostatin receptor (SSTR) agonists (177Lu-DOTATATE or 177Lu-DOTATOC) showed limited response rate and durability. The novel SSTR antagonist DOTA-LM3 labelled with terbium-161, which co-emits conversion and Auger electrons in addition to β- particles, potentially increasing tumour doses and offering a more effective treatment for micro metastases.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Westerbergh F, McDougall L, Christ E, Nicolas G,

Keywords: Radionuclide therapy, PRRT, Auger electrons, Conversion electrons, Terbium-161, radiolabelled somatostatin antagonist, neuroendocrine tumour,